Literature DB >> 28835974

[Hypercalcemic crisis and hypocalcemic tetany].

C Kasperk1.   

Abstract

A serum calcium level >3.5 mmol/l together with clinical symptoms such as muscle weakness, fatigue, nausea, vomiting, pancreatitis or even coma are characteristic for a hypercalcemic crisis (HC). Primary hyperparathyroidism (1HPT) and malignancy-associated hypercalcemia are the most frequent causal diseases for a HC. The analysis of serum levels for calcium, phosphorous, intact parathyroid hormone, electrophoresis and renal function parameters indicate which further radiological, scintigraphic or serum diagnostic steps are adequate to identify the cause of the patient's acute situation (i. e. most frequently 1HPT or malignant disease with bone involvement, e. g. myeloma) and thus to initiate the required surgical or oncological intervention. However, the primary goals in the treatment of HC include correcting dehydration and improving kidney function, lowering calcium levels and decreasing osteoclastic bone resorption. The goals are accomplished by volume repletion, forced diuresis, antiresorptive agents and hemodialysis on an intensive care unit. Hypocalcemic tetany (HT) is the consequence of severely lowered calcium levels (<2.0 mmol/l), usually in patients with chronic hypocalcemia. The causal disease for hypocalcemic tetany is frequently a lack of parathyroid hormone (PTH), (e. g. as a complication of thyroid surgery) or, rarely, resistance to PTH. HT due to severe and painful clinical symptoms requires rapid i. v. calcium replacement by central venous catheter on an intensive care unit. For the treatment of chronic hypocalcemia oral calcium and 25OH-vitamin D or even 1,25(OH)2-vitamin D3 and magnesium supplements may be necessary to achieve the desired low normal calcium levels. Thiazides are useful to reduce renal calcium loss and to stabilize the calcium levels. Some patients continue to exhibit clinical symptoms despite adequate calcium levels; in these cases s. c. parathyroid hormone 1-84 should be considered to stabilize calcium levels and to lower the dosage of calcium and vitamin D supplements.

Entities:  

Keywords:  Hypercalcemia; Hyperparathyroidism; Hypocalcemia; Hypoparathyroidism; Neoplasms

Mesh:

Substances:

Year:  2017        PMID: 28835974     DOI: 10.1007/s00108-017-0311-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  Parathyroidectomy for hypercalcemic crisis: 40 years' experience and long-term outcomes.

Authors:  Jennifer Cannon; John I Lew; Carmen C Solórzano
Journal:  Surgery       Date:  2010-08-30       Impact factor: 3.982

Review 2.  Clinical practice. Hypoparathyroidism.

Authors:  Dolores Shoback
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

3.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

Review 4.  Hypercalcemic crisis: a clinical review.

Authors:  Shazia Ahmad; Gayatri Kuraganti; Devin Steenkamp
Journal:  Am J Med       Date:  2014-10-17       Impact factor: 4.965

5.  Therapy of hypoparathyroidism with intact parathyroid hormone.

Authors:  M R Rubin; J Sliney; D J McMahon; S J Silverberg; J P Bilezikian
Journal:  Osteoporos Int       Date:  2010-01-22       Impact factor: 4.507

Review 6.  A practical approach to hypercalcemia.

Authors:  Mary F Carroll; David S Schade
Journal:  Am Fam Physician       Date:  2003-05-01       Impact factor: 3.292

7.  Natpara for the treatment of hypoparathyroidism.

Authors:  Gemma Marcucci; Giuseppe Della Pepa; Maria Luisa Brandi
Journal:  Expert Opin Biol Ther       Date:  2016-11       Impact factor: 4.388

Review 8.  Hypoparathyroidism.

Authors:  Hafsah Al-Azem; Aliya A Khan
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-31       Impact factor: 4.690

Review 9.  Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature.

Authors:  Ke Chen; Yanhong Xie; Liling Zhao; Zhaohui Mo
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

10.  Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.

Authors:  Bart L Clarke; Tamara J Vokes; John P Bilezikian; Dolores M Shoback; Hjalmar Lagast; Michael Mannstadt
Journal:  Endocrine       Date:  2016-10-12       Impact factor: 3.633

View more
  2 in total

1.  The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs.

Authors:  Shin Tokunaga; Takehisa Kawata
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

2.  Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study.

Authors:  Tobias Rupp; Emil von Vopelius; André Strahl; Ralf Oheim; Florian Barvencik; Michael Amling; Tim Rolvien
Journal:  Osteoporos Int       Date:  2022-06-25       Impact factor: 5.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.